1743-422X-5-99 1743-422X Research <p>A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: Potential impact on CTL epitopes</p> Srinivasan Alagarsamy alagarsamy.srinivasan@gmail.com Ayyavoo Velpandi velpandi@pitt.edu Mahalingam Sundarasamy Mahalingam@iitm.ac.in Kannan Aarthi akannan@wellesley.edu Boyd Anne annekboyd@gmail.com Datta Debduti debduti.datta@gmail.com Kalyanaraman S Vaniambadi vs.kaly@ablinc.com Cristillo Anthony Anthony.cristillo@ablinc.com Collman G Ronald collmanr@mail.med.upenn.edu Morellet Nelly Morellet@pharmacie.univ-paris5.fr Sawaya E Bassel sawaya@temple.edu Murali Ramachandran murali@xray.med.upenn.edu

Thomas Jefferson University, Department of Microbiology and Immunology, Jefferson Alumni Hall Rm 461, 1020 Locust Street, Philadelphia, PA 19107, USA

University of Pittsburgh, Department of Infectious Diseases & Microbiology, Parran Hall Rm 439, 130 DeSoto Street, Pittsburgh, PA 15261, USA

Department of Biotechnology, Indian Institute of Technology Madras, Chennai 600036, India

Wellesley College, 21 Wellesley College Rd Unit 7430, Wellesley, MA 02481, USA

Advanced Bioscience Laboratories, Inc., 5510 Nicholson Lane, Kensington, MD 20895, USA

University of Pennsylvania School of Medicine, 522 Johnson Pavilion, 36th and Hamilton Walk, Philadelphia PA 19104, USA

Unite de Pharmacologie Chimique et Genetique, INSERM, Avenue de l'Observatoire, Paris Cedex 06, France

Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA 19122, USA

University of Pennsylvania School of Medicine, Dept of Pathology and Laboratory Medicine, 243 John Morgan, Philadelphia PA 19104, USA

 Virology Journal 1743-422X 2008 5 1 99 http://www.virologyj.com/content/5/1/99 18721481 10.1186/1743-422X-5-99 07 7 2008 23 8 2008 23 8 2008 2008 Srinivasan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The enormous genetic variability reported in HIV-1 has posed problems in the treatment of infected individuals. This is evident in the form of HIV-1 resistant to antiviral agents, neutralizing antibodies and cytotoxic T lymphocytes (CTLs) involving multiple viral gene products. Based on this, it has been suggested that a comprehensive analysis of the polymorphisms in HIV proteins is of value for understanding the virus transmission and pathogenesis as well as for the efforts towards developing anti-viral therapeutics and vaccines. This study, for the first time, describes an in-depth analysis of genetic variation in Vpr using information from global HIV-1 isolates involving a total of 976 Vpr sequences. The polymorphisms at the individual amino acid level were analyzed. The residues 9, 33, 39, and 47 showed a single variant amino acid compared to other residues. There are several amino acids which are highly polymorphic. The residues that show ten or more variant amino acids are 15, 16, 28, 36, 37, 48, 55, 58, 59, 77, 84, 86, 89, and 93. Further, the variant amino acids noted at residues 60, 61, 34, 71 and 72 are identical. Interestingly, the frequency of the variant amino acids was found to be low for most residues. Vpr is known to contain multiple CTL epitopes like protease, reverse transcriptase, Env, and Gag proteins of HIV-1. Based on this, we have also extended our analysis of the amino acid polymorphisms to the experimentally defined and predicted CTL epitopes. The results suggest that amino acid polymorphisms may contribute to the immune escape of the virus. The available data on naturally occurring polymorphisms will be useful to assess their potential effect on the structural and functional constraints of Vpr and also on the fitness of HIV-1 for replication.

Introduction

Humoral and cellular responses have been implicated in controlling viral and bacterial infections in addition to the host's innate immune responses. This is, indeed, demonstrated in the context of HIV-1 infection 123. Specifically, CTL responses against the virus have been shown to limit the virus replication at a low level in the infected individuals. This is evident in the inverse correlation of CTL responses vs. virus load observed in acutely infected individuals 456. Utilizing the rhesus macaque/SIV infection model, a suppressive effect on virus replication was shown for CTLs 7. However, the initial CTL responses are not able to contain the virus at a later stage, possibly due to the emergence of viral variants that evade the immune responses resulting in continued virus replication 89. Hence, an understanding of the CTL escape variants of HIV is important both in natural viral infections and also in the context of vaccine-induced immunity for developing effective CTL based polyvalent vaccines for containing diverse HIV-1 strains 10. This is an area of research which is actively being pursued by several investigators 1112.

The genome of HIV-1 has been shown to code for two regulatory proteins (Tat and Rev) and four auxiliary proteins (Vif, Vpr, Vpu and Nef) in addition to the Gag, Pol, and Env structural proteins 13. The regulatory proteins Tat and Rev are essential for virus replication. Rev is involved in the transport of genomic and partially spliced subgenomic mRNA from the nucleus to the cytoplasm 14. Tat is known as an activator of transcription of viral and cellular RNA. Vif plays an important role in HIV-1 replication in peripheral blood mononuclear cells (PBMC). Specifically, Vif prevents hypermutation in the newly made viral DNA through its interaction with APOBEC3G 1516. Vpr is known for its incorporation into the virus particles. The interaction of Vpr with the Gag enables its incorporation into the virus particle. Vpr is a multifunctional protein and is involved in the induction of apoptosis, cell cycle arrest, and transcriptional activation 17. Vpu plays a role in the particle release and degradation of CD4 141819. The features of Nef include downregulation of cell surface receptors, interference with signal transduction pathways, enhancement of virion infectivity, induction of apoptosis in bystander cells, and protection of infected cells from apoptosis 2021222324.

Based on the data reported so far, it is clear that HIV-1 employs multiple strategies to successfully replicate in the infected individuals 142526. The enormous genetic variation that is generated through errors of reverse transcriptase enzyme may provide a pool of variants to evade the host immune responses against the virus and also result in the emergence of drug resistant viruses during treatment. In addition, it is also likely that the immunosuppressive effects of HIV-1 encoded proteins may attenuate the host immune responses in favor of the virus.

Upon infection of target cells by the virus, viral proteins are synthesized for carrying out the functions related to the virus replication and also exert effect on specific host cell functions. In addition, viral proteins are also targeted to the proteosomal degradation pathway. This process results in the generation of peptides, which are then translocated to the ER through TAP and are presented on the cell surface in association with human leukocyte antigen (HLA) class I molecules. The genetic variability present in the coding sequences of the virus may result in viral proteins with alterations in the CTL epitopes, which may lead to defective processing, presentation or lack of recognition of the epitope by the reactive CTLs. This is the likely mechanism of the CTL escape by HIV-1 and other viruses. The presence of multiple CTL epitopes has been demonstrated in HIV-1 proteins including Gag, Pol, Vif, Vpr, Tat, Rev, Vpu, Env and Nef. Though the characterization of the epitopes with respect to the viral proteins is achievable in individual cases, such an analysis at a population level is difficult to carry out for the following reasons: i) HIV-1 exhibits high genetic variation in different regions of the genome. The extent of heterogeneity among circulating HIV-1 strains is described to be in the range of 20% or more in relatively conserved proteins and up to 35% for Env protein 11. In addition, there is also extensive diversity among HIV-1 within a subtype, ii) There are multiple subtypes of HIV-1, and iii) There are variables at the HLA loci. On the other hand, this limitation can be overcome to some extent by utilizing alternative approaches where information about CTL epitopes and their variants can be inferred from the sequences available for HIV-1 272829. The HIV sequence database has information about the viral isolates from different parts of the world. This information can be used as a source to assess the extent of naturally occurring polymorphisms and their potential impact on CTL epitopes. We hypothesize that mutations or alterations in the residues which are part of the CTL epitope in the Vpr molecule are likely to affect the epitope at multiple levels (processing and recognition of the epitope). Recently, studies have addressed this issue using full length or partial HIV-1 genome sequences 30. This has prompted us to carry out a comprehensive analysis of the extent of variation at the amino acid level in the auxiliary gene product Vpr of HIV-1.

The underlying reasons for the selection of Vpr for a comprehensive analysis are the following: i) Vpr is a virion associated protein, ii) Vpr plays a critical role for the replication of virus in macrophages, iii) Vpr is a transcriptional activator of HIV-1 and heterologous cellular genes, iv) Vpr arrests cells at G2/M, v) Vpr induces apoptosis in diverse cell types, vi) Vpr exhibits immune suppressive effect, vii) Vpr is present in the body fluids as an extracellular protein, viii) Vpr is highly immunogenic, ix) Vpr is a small protein comprising only 96 amino acids and x) Structural information for the whole Vpr molecule is available through NMR 1731323334. These features enable a detailed analysis of the polymorphisms in Vpr with respect to CTL epitopes, structure-function of the protein, and fitness of the virus for replication.

In this study, we have analyzed the predicted amino acid sequences of Vpr from global HIV-1 isolates available through the HIV database. Specifically, the extent of genetic variation in Vpr in the form of polymorphisms at the individual amino acid level was comprehensively analyzed. Several of the amino acid polymorphisms were found to be part of the experimentally verified and predicted CTL epitopes. The location and nature of the variant amino acid were found to affect the CTL epitope considerably. Hence, our results provide a glimpse into the genetic footprints of immune evasion in Vpr.

Materials and methods

The goal of our studies is to assess the nature and extent of polymorphisms at the level of individual residues in the Vpr molecule. The sequences considered here comprise Vpr sequences derived from all the major subtypes of HIV-1. The details regarding the subtypes and the number of sequences from each subtype are presented in Table 1 and are taken from the HIV database http://www.hiv.lanl.gov35363738. In addition, we have included Vpr sequences derived from HIV-1 positive long term non-progressors (McKeithen et al., unpublished data). It should be noted that we have also included Vpr from SIV isolated from chimpanzees, as this is likely the progenitor virus for HIV-1. Vpr sequences from the database were accessed in January of 2007. The deletions in the Vpr molecule were excluded from our analysis. The alignment of Vpr sequences (which is available from the authors upon request) was analyzed manually for variant amino acids at the level of individual residue in Vpr from global and distinct subtypes of HIV-1.

<p>Table 1</p>

Vpr sequences used for the analysis of amino acid polymorphisms

Subtype Designation

Number of Vpr Sequences

A

67

B

294

C

185

D

44

F1

6

F2

4

G

8

H

3

J

2

K

2

AE

45

AG

39

AB

3

Cpx

28

Others (includes DF, BC, CD, BG, 01B, A1C, A1D, A1G, etc)

198

O

39

N

3

Cpz

4

Unclassified

3

Results

Characteristics of Vpr sequences selected for this study

The alignment of Vpr sequences has enabled us to analyze the differences at the level of each residue from diverse HIV-1 isolates. A total of 976 Vpr sequences have been used for alignment. The polymorphisms, with respect to the length, have been noted in Vpr by several investigators 1739. As this may pose problem for our analysis, our alignment does not take into account both deletions and insertions. The Vpr alleles are from diverse subtypes and include 67, 294, 185 and 44 Vpr sequences representing subtype A, B, C, and D, respectively (Table 1). The O, AE, AG, and cpx groups represent 39, 45, 39 and 28 Vpr sequences, respectively. Since the Vpr sequences are derived from different sources such as viral RNA, cloned viral DNA and proviral DNA from tissues, we have not made attempts to classify them in our analysis.

Amino acid polymorphisms in the predicted Vpr sequences

Recently, the structure of full length Vpr has been resolved by NMR 40. According to this study, Vpr consists of a flexible N-terminal domain (amino acids 1–16), helical domain I (HI) (residues 17–33), turn (residues 34–37), helical domain II (HII) (residues 38–50), turn (residues 51–54), helical domain III (HIII) (residues 55–77), and a flexible C-terminal domain (residues 78–96). Based on this structure, the polymorphisms observed in Vpr are presented with respect to the individual domain.

N-terminus of Vpr (residues 1–16)

The results presented in Table 2 regarding the N-terminal domain of Vpr show that all the residues excluding the initiator methionine are susceptible for alterations. The altered amino acids or polymorphisms at each residue are indicated as variant amino acids or substitutions. For convenience, we have used Vpr from NL4-3 proviral DNA as a reference sequence. The amino acid sequence of NL4-3 Vpr is similar to HIV-1 subtype B consensus Vpr except for residues 28(S), 77(Q) and 83(I). Interestingly, the residue 9, which is G, has only one variant amino acid. In an earlier study, it was noted that a change in residue 3 from Q to R was not associated with cytopathic effect 41. In our analysis, variant amino acids H, L, M, and P were also noted for Q. Studies involving synthetic peptides corresponding to the N-terminus and also the full-length Vpr molecule have shown that the Vpr sequence (residues PHN) have the ability to form a γ-turn. The residue 15(H) exhibits eleven, residue 16 (N) shows ten and residue 14 (P) shows four variant amino acids. While residue 2 has two, residues 5 and 12 register three variant amino acids. Residues 3, 4, 6, 7, 8, 10, 11, and 13 contain multiple variant amino acids ranging from five to eleven. The N-terminal domain contains a total of 79 variant amino acids. Of these, non-conserved substitutions correspond to about 80% of the residues.

<p>Table 2</p>

The polymorphisms in the N-Terminus of Vpr (residues 1–16)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of different clades

Number of variants

1

M

none

none

2

E

D, K

2

3

Q

H, L, M, P, R

5

4

A

D, F, I, L, N, P, S, T, V

9

5

P

L, Q, S

3

6

E

A, D, G, K, Q, S, V

7

7

D

E, G, H, N, V

5

8

Q

A, E, H, L, P, R

6

9

G

R

1

10

P

A, L, N, S, T

5

11

Q

A, E, S, P

4

12

R

E, G, K

3

13

E

A, D, I, G, Q, V

6

14

P

H, L, Q, S

4

15

Y

C, D, F, G, H, L, M, N, P, S, V

11

16

N

A, D, E, H, I, P, Q, R, S, T

10

The impact of the majority of the polymorphisms on Vpr functions is not clear. Substitution of alanine for proline at residue 5 and 10 showed less or increased virion incorporation of Vpr, respectively 42. Similarly, substitution of alanine for residue 12 reduced the cell cycle arrest function of Vpr 43. On the other hand, substitution at residue 13 and 14 showed an increase in cell cycle arrest 4244. Hence, the naturally occurring polymorphisms are likely to affect the functions of Vpr.

Helical domain I (HI residues 17–33)

NMR studies of full length Vpr show that a region comprising the residues 17–33 adapt a helical structure. This was also predicted by several algorithms. The polymorphisms observed for the residues 17–33 are presented in Table 3. The characteristics of the residues with respect to the variant amino acids are the following: residues 18, 23 and 26 show two substitutions; residue 20 has three substitutions; residues 25, and 29 show four substitutions; residues 21, 24, 27, 30 and 32 show five substitutions; and residues 17, 22, and 31 register six substitutions and residue 19 has eight substitutions. Interestingly, residue 28 exhibits the highest number of substitutions and residue 33 has only one substitution. This domain exhibits a total of 80 variant amino acids and 61 of them are of non-conservative in nature.

<p>Table 3</p>

The polymorphisms in Helical Domain I of Vpr (residues 17–33)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of different clades

Number of variants

17

E

A, D, G, Q, T, V

6

18

W

G, R

2

19

T

A, I, L, M, P, R, S, V

8

20

L

I, M, V

3

21

E

A, D, G, K, T

5

22

L

F, I, M, P, T, V

6

23

L

S, V

2

24

E

D, G, K, Q, R

5

25

E

A, D, G, K

4

26

L

F, I

2

27

K

I, M, N, Q, R

5

28

S

A, D, E, G, H, I, K, N, Q, R, T, V

12

29

E

D, G, Q, V

4

30

A

D, P, S, T, V

5

31

V

A, D, I, L, M, T

6

32

R

G, K, Q, T, W,

5

33

H

R

1

Several laboratories including ours have reported on the importance of residues in the helical domain I for Vpr functions. Substitution of a proline residue for glutamic acid (residue 17, 21, 24, 25, and 29) has a drastic effect on the stability, subcellular localization, and virion incorporation of Vpr 444546474849. The variant amino acids noted in this domain have the potential to destabilize and disrupt the function of Vpr. Similarly, substitution of alanine for leucine residue affected the stability and virion incorporation of Vpr 454850515253. Based on the studies reported, varying amino acid arginine for histidine at residue 33 will affect the subcellular localization and virion incorporation of Vpr 54.

Interhelical domain I (residues 34–37)

This region is present between helical domains I and II and comprises only four residues. It has been shown that residues in this region have the ability to form a γ-turn. The naturally occurring polymorphisms in this region are presented in Table 4. Site-specific mutagenesis studies have shown an important role for residues in subcellular localization, cell cycle arrest, apoptosis and virion incorporation of Vpr 4244515556. Residues 34 and 35 show only three substitutions. On the other hand, residue 36 and 37 register 10 and 16 substitutions, respectively. The variant amino acids reach a total of 31 and 21 of them are of non-conservative in nature.

<p>Table 4</p>

The polymorphisms in the Interhelical Domain 1 of Vpr (residues 34 – 37)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of different clades

Number of variants

34

F

L, V, Y

3

35

P

H, L, S

3

36

R

G, I, K, M, N, P, Q, S, T, W

10

37

I

A, D, E, G, H, K, L, M, N, P, Q, R, S, T, V, Y

16

Helical domain II (residues 38–50)

Studies with peptide (1–50 amino acids) and full-length Vpr have shown that residues 38–50 correspond to helical domain II of Vpr. The naturally occurring polymorphisms corresponding to the residues in this region are presented in Table 5. The characteristics of the substitution are the following: residues 39 and 47 exhibit a single substitution; residues 43, 46 and 50 record two substitutions; residue 38 shows four substitutions; residues 42, 45 and 49 show five substitutions; and residues 40 and 44 have eight substitutions. Nine and thirteen substitutions were noted for residues 41 and 48, respectively. This domain contains 64 variant amino acids and non-conservative substitutions correspond to 41 residues. Several laboratories have carried out experiments addressing the role of residues in this region by utilizing site-specific mutagenesis. The alteration of hydrophobic residues severely affected the virion incorporation and transcriptional activation of Vpr 43445056.

<p>Table 5</p>

The polymorphisms in Helical Domain II of Vpr (residues 38 – 50)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of different clades

Number of variants

38

W

C, F, T, Y

4

39

L

F

1

40

H

I, L, M, N, Q, R, T, Y

8

41

N

A, D, E, G, H, Q, R, S, W

9

42

L

C, I, F, M, V

5

43

G

E, R

2

44

Q

E, H, L, K, N, R, T, V

8

45

H

F, L, Q, W, Y

5

46

I

D, V

2

47

Y

H

1

48

E

A, D, G, H, I, K, N, Q, R, S, T, V, Y

13

49

T

H, N, M, S, Y

5

50

Y

H, S

2

Interhelical domain II (residues 51–54)

This region is located between helical domains II and III. Of the four residues which are part of this domain, only the residue G51 has been shown to reduce G2/M cell cycle arrest through alanine substitution 44. The naturally occurring polymorphisms corresponding to the residues in this region are presented in Table 6. The characteristics of the substitutions are the following: residue 54 shows two substitutions; residue 51 shows three substitutions; residue 52 shows four substitutions and residue 53 shows five substitutions. The variant amino acids reach a total of fourteen and the majority of them are non-conservative substitutions.

<p>Table 6</p>

The polymorphisms in Interhelical Domain II of Vpr (residues 51 – 54)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of different clades

Number of variants

51

G

E, K, R

3

52

D

A, G, I, N

4

53

T

A, L, N, P, S

5

54

W

G, R

2

Helical domain III (residues 55–77)

The presence of helical domain III has been demonstrated by NMR 40. Several laboratories including ours have shown the importance of this domain for the function of Vpr. The naturally occurring polymorphisms noted for the residues in this region are presented in Table 7. The characteristics of the substitutions are the following: residues 56, 64, 65, 71 and 75 exhibit two substitutions; residues 69, 70, 72, 73 and 76 register three substitutions; residues 57, 66 and 68 show four substitutions; residues 60, 61 and 67 show six substitutions; residues 62 and 63 have seven substitutions; residue 74 has eight substitutions; residues 58, 59, and 77 exhibit ten substitutions; and residue 55 shows eleven substitutions. While the variant amino acids reach a total of 108, 65 of them are of non-conservative nature. This region comprises LXXLL motif which is important for subcellular localization and also influences the virion incorporation of Vpr 44575859606162. Additionally the LXXLL domain is also involved in Vpr-GR interaction and its subsequent role in virus replication 6364.

<p>Table 7</p>

The polymorphisms in Helical Domain III of Vpr (residues 54–77)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of different clades

Number of variants

55

A

E, G, I, L, M, P, Q, R, S, T, V

11

56

G

E, R

2

57

V

A, L, M, W

4

58

E

A, G, I, K, L, M, Q, R, T, V

10

59

A

D, F, I, L, M, N, P, S, T, V

10

60

I

F, L, M, T, V, Y

6

61

I

A, L, M, T, V, Y

6

62

R

I, K, L, Q, S, T, W

7

63

I

F, L, M, S, T, V, Y

7

64

L

F, V

2

65

Q

H, R

2

66

Q

H, K, L, R

4

67

L

A, F, I, M, P, Q

6

68

L

I, M, P, R

4

69

F

L, S, V

3

70

I

A, T, V

3

71

H

L, Y

2

72

F

S, Y, L

3

73

R

G, S, T

3

74

I

F, H, L, M, N, S, T, V

8

75

G

K, R

2

76

C

G, S, Y

3

77

R

A, H, L, K, N, P, Q, S, T, W

10

C-terminus of Vpr (residues 78–96)

The naturally occurring polymorphisms corresponding to the residues in the C-terminus of Vpr are presented in Table 8. The characteristics of the substitutions for the residues in this region are the following: residue 80 has only two substitutions; residues 78, 79, 82 and 92 have three substitutions; residues 81 and 90 have four substitutions; residues 91 and 96 have five substitutions. All of the other residues have substitutions ranging from six to thirteen. Of the 124 variant amino acids in this domain, 100 of them are of non-conservative nature.

<p>Table 8</p>

The polymorphisms in the Carboxy-Terminal Region of Vpr (residues 78–96)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of different clades

Number of variants

78

H

L, R, Y

3

79

S

N, R, T

3

80

R

A, K

2

81

I

G, M, R, V

4

82

G

A, D, S

3

83

V

H, I, L, M, N, P, T, V

8

84

T

A, F, G, I, L, M, N, P, Q, S, V, W, Y

13

85

R

A, H, I, L, P, Q, T, V, Y

9

86

Q

E, G, H, M, P, R, S, T, V, Y

10

87

R

A, E, G, K, M, N, P, Q, S, T

10

88

R

A, E, G, I, S, T

6

89

A

D, E, G, I, L, N, P, R, S, T, V

11

90

R

G, I, N, S

4

91

N

D, H, I, K, S

5

92

G

A, E, R

3

93

A

D, F, G, L, M, N, P, S, T, V

10

94

S

D, E, F, G, H, N, R, V

8

95

R

A, D, G, I, K, P, S, T

8

96

S

F, P, T, V, Y

5

This domain contains multiple arginine and serine residues. It has been reported that the arginine residues are important for the cell cycle arrest and subcellular localization 6566. Vpr is known to undergo post-translational modification and the serine residues located at 28, 79, 94, and 96 positions of the protein serve as substrates for the phosphorylation 67. Vpr, devoid of phosphorylation through site-specific mutagenesis, severely affects replication of HIV-1 in macrophages 68. Residue 28 contains equivalent proportion of amino acids N (44%) and S (48%) and Vpr of SIV cpz contains N or T at this position. On the other hand, serine residues at 79, 94, and 96 are conserved in SIV cpz Vpr.

The naturally occurring polymorphisms for the whole Vpr molecule reach a total of 498 substitutions. The non-conservative variant amino acids correspond to 72%. It is important to note that all the residues in Vpr have the propensity to accept variant amino acids. The data presented here also reveal that the variant amino acids noted with respect to some residues are identical. These include residues 60(I), 61(I), 34(F), 71(H) and 72(F). We have carried out a detailed analysis of the variant amino acids noted in distinct subtypes (A, B, C, and D) of HIV-1. Such an analysis could not be carried out for several groups because of the limited information available regarding Vpr alleles. The data generated for subtype B Vpr alleles are presented in Tables 9, 10, 11, 12, 13, 14, 15. The analysis of subtype B involves a total of 275 Vpr alleles. As expected, the extent of polymorphisms in subtype B is less in comparison to the total polymorphisms noted with all the Vpr alleles. Interestingly, there are several residues that did not have any variant amino acids. These include residues 9, 18, 26, 34, 35, 38, 42, 46, 64, 66, and 79. On the other hand, the residues without variant amino acids in subtype C are different from that of subtype B except for 9, 26, and 64. In addition, the frequency of variant amino acids at the level of each residue was also determined for subtype B Vpr. The results indicate that the frequency of variant amino acids is low in most cases (0.4–1.1%) except for the residues 7, 19, 37, 41, 45, 55, 60, 63, 77, 80, 84, 85, 86, 89, and 93. Analysis involving a large number of Vpr alleles also showed frequency patterns consistent with the data presented in Tables 9, 10, 11, 12, 13, 14, 15. With respect to the N-terminus domain (Table 9), the residue 7 (D) has residue N substitution with a frequency of 6.2%. Also, while the reference Vpr allele has Y at position 15, which is the predominant amino acid (85%), the variant amino acid F occurs to a limited extent (6.9%). Similar scenario is also applicable to the residues 28, 77, and 83 (Tables 10 and 15). The residue R 80, which has been implicated in cell cycle arrest function of Vpr, exhibits substitution of A with a frequency of 5.1%.

<p>Table 9</p>

The frequency of variant amino acids in the N-Terminus of Vpr (Residues 1–16)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of subtype B*

1

M

no change

2

E

D (0.4)

3

Q

H (0.4), R (1.8)

4

A

D (0.7), T (0.4), V (1.1)

5

P

L (0.4), S (0.4)

6

E

A (1.1), D (0.4), K (1.1), Q (0.7)

7

D

N (6.2), V (0.4)

8

Q

H (1.1)

9

G

no change

10

P

L (0.4), S (0.7)

11

Q

A (0.7), E (0.4), P (1.8), S (1.8)

12

R

K (0.4)

13

E

I (0.4), Q (1.1), V (0.7)

14

P

Q (0.4), S (0.7)

15

Y

C (0.4), D (0.4), F (6.9), H (5.0), N (0.7), S (0.4), V (0.4)

16

N

A (0.4), H (1.1), I (0.4), Q (0.7), P (0.4), R (0.4), S (0.4), T (0.7)

*275 Vpr alleles were used for analysis.

The numbers in the parentheses represent the percent frequency of the variant amino acid in the Vpr alleles analyzed.

 <p>Table 10</p>

The frequency of variant amino acids in Helical Domain I of Vpr (Residues 17–33)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of subtype B

17

E

A (3.3), D (0.4), G (0.4), Q (2.2), V (0.4)

18

W

no change

19

T

A (12.7), R (0.4)

20

L

I (4.4)

21

E

G (0.4)

22

L

F (0.4), I (1.1), P (0.4)

23

L

V (0.4), S (0.4)

24

E

G (0.4), K (0.4), Q (0.7), R (0.4)

25

E

A (0.4), D (2.9), K (0.4)

26

L

no change

27

K

N (0.4)

28

S

G (0.4), H (0.7), N (43.5), R (4.7), T (2.5)

29

E

D (0.4), V (0.4)

30

A

P (0.4)

31

V

A (0.4), D (0.4), I (0.4), L (0.4), T (0.4)

32

R

K (3.6), Q (0.4), W (0.4)

33

H

R (3.6)

 <p>Table 11</p>

The frequency of variant amino acids in the Interhelical Domain 1 of Vpr (Residues 34–37)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of subtype B

34

F

no change

35

P

no change

36

R

G (1.1), W (1.8), S (1.5)

37

I

A (1.5), E (3.6), G (1.1), K (0.4), L (1.8), M (2.5), N (0.4), P (16), R (0.4), S (0.7), T (7.6), V (19.3)

 <p>Table 12</p>

The frequency of variant amino acids in Helical Domain II of Vpr (Residues 38–50)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of subtype B

38

W

no change

39

L

F (0.4), I (0.4)

40

H

L (2.2), N (0.4), Q (1.5), R (0.4), T (0.4), Y (0.4)

41

N

A (0.7), D (0.7), E (0.4), G (52.0), S (30.5)

42

L

no change

43

G

E (0.4), R (0.4)

44

Q

R (0.4)

45

H

F (0.7), L (1.1), Q (0.4), Y (24.4)

46

I

no change

47

Y

H (0.4)

48

E

A (0.4), D (2.5), G (1.1), K (0.4), Q (0.4), V (0.4)

49

T

N (0.7)

50

Y

S (0.4)

 <p>Table 13</p>

The frequency of variant amino acids in Interhelical Domain II of Vpr (Residues 51 – 54)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of subtype B

51

G

E (0.7), K (0.4)

52

D

N (0.7), I (0.4)

53

T

A (0.4), L (0.4)

54

W

R (0.4), G (0.4)

 <p>Table 14</p>

The frequency of variant amino acids in Helical Domain III of Vpr (Residues 55–77)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of subtype B

55

A

E (2.2), P (1.1), Q (0.4), T (19.6), V (1.8)

56

G

R (0.4), E (0.7)

57

V

W (0.4)

58

E

G (1.1), I (0.4), K (1.1), Q (0.7), V (0.4)

59

A

L (0.4), P (0.4), S (0.4), V (0.4)

60

I

L (16.4)

61

I

L (0.4), M (1.1), T (3.3), V (1.5)

62

R

K (0.7), L (0.4), S (0.4)

63

I

M (5.8), S (1.8), T (11.3), V (1.8)

64

L

no change

65

Q

H (0.4)

66

Q

no change

67

L

M (1.5), P(0.7)

68

L

M (1.5)

69

F

L (1.8)

70

I

T (2.9), V (1.1)

71

H

L (0.4), Y (0.4)

72

F

S (1.5), Y (0.4)

73

R

T (0.7)

74

I

L (0.4), M (0.4), V (0.4)

75

G

R (1.1)

76

C

G (1.1)

77

R

H (5.5), Q (42.5)

 <p>Table 15</p>

The frequency of variant amino acids in the Carboxy-Terminal Region of Vpr (Residues 78–96)

Residue

Residues in NL4-3 Vpr

Variant residue(s) noted in viruses of subtype B

78

H

L (0.7)

79

S

no change

80

R

A (5.1)

81

I

G (0.4), M (0.7), V (0.4)

82

G

D (0.7), S (0.7)

83

V

I (86.9), L (0.4), T (0.7)

84

T

A (0.4), F (0.4), G (0.7), I (30.9), L (2.5), M (0.4), N (0.7), S (0.4), V (0.4)

85

R

H (0.4), I (0.4), L (2.5), P (15.6), Q (28.4), T (0.4), Y (1.1)

86

Q

M (0.4), P (1.1), R (21.1), S (1.5), V (1.1)

87

R

A (0.4), G (1.5), K (0.4), M (0.4), N (0.4), S (3.3), T (3.6)

88

R

A (2.2), G (1.5), I (0.4), S (0.4), T (0.7)

89

A

E (0.7), G (0.4), P (0.7), R (2.2), S (2.2), T (10.2), V (0.4)

90

R

G (0.4), N (0.4), S (0.4)

91

N

D (1.5), H (0.4), I (0.4), K (0.4)

92

G

A (0.4), E (0.4), R (0.7)

93

A

D (0.4), L (0.4), P (0.7), S (6.5), T (2.2), V (0.4)

94

S

F (0.4), G (2.5), N (1.1), R (3.3), V (0.4)

95

R

A (0.4), D (0.4), I (0.4), K (0.4), T (1.1), S (0.4)

96

S

P (4.0)

Impact of amino acid polymorphisms on defined and predicted CTL epitopes in Vpr

It has been shown that a single amino acid change in the epitope enables the virus to evade the T cell surveillance 969. Hence, it is of interest to analyze the polymorphisms in the context of both experimentally verified and predicted CTL epitopes. As Vpr is a highly immunogenic protein, several CTL epitopes have been already defined 12. CD8+ epitopes are contiguous and nine amino acids long. The experimentally verified CTL epitopes in Vpr are presented in Table 16 with their location in the protein. We have presented the overall amino acid polymorphisms for each of the epitope. The experimentally verified CTL epitopes cluster in the region covering 1–70 residues of Vpr. The total amino acid polymorphisms range from 36 to 107 for the individual epitopes. For example, the CTL epitope comprising the residues REPHNEWTL contains 53 variant amino acids. Residues at position 1 to 9 of the epitope show 3, 6, 4, 11, 10, 6, 2, 8, and 3 variant amino acids, respectively.

<p>Table 16</p>

The extent of amino acid polymorphisms in experimentally defined CTL epitopes

Location of the epitope in Vpr

Amino acid sequence

Total number of variant amino acids in the CTL epitope

Reference

1 – 18

MEQAPENQGLQREPYNEW

87

86

9 – 26

GPQREPYNEWTLELLEEL

87

87

12 – 20

REPHNEWTL

53

28 88 89

19 – 28

TLEILEELKN

51

86

25 – 40

ELKNEAVRHFPRIWLH

87

90

29 – 37

EAVRHFPRI

52

91 92 93 94

30 – 38

AVRHFPRIW

52

28 88 95

31 – 50

VRHFPRWLHSLGQYIYETY

107

96

31 – 39

VRHFPRIWL

48

97

34 – 42

FPRIWLHGL

58

28 87 89 97 98 99 100 101 102 103

41 – 49

SLGQHIYET

49

99

41 – 57

GLGQYIYETYGDTWTGV

82

87

46 – 54

IYETYGDTW

36

104

48 – 57

ETYGDTWTGV

50

87 97

52 – 62

DTWAGVEAIIR

66

97

53 – 63

TWAVEAIIRI

69

92

55 – 70

AGVEAIIRILQQLLFI

86

28

59 – 67

AIIRILQQL

49

10 28 89 96 98 105 106

62 – 70

RILQQLLFI

38

89 98 106

In addition, we have also utilized bioinformatics approach to assess the effect of polymorphisms on CTL epitope http://Bimas.dcrt.nih.gov/molbio/hla-bind. The predicted CTL epitopes with respect to several HLA class I alleles are presented in Table 17. The impact of polymorphisms on the CTL epitope was assessed by determining the estimate of half-time of disassociation of the molecule containing the epitope. For this purpose, we have considered 3, 1, 2, and 6 epitopes corresponding to HLA-A2, Cw-4, HLA B-7 and HLA B-2705, respectively. The influence of variant amino acids on the CTL epitope is presented in Table 18, 19, 20 with respect to HLA-A2 molecule. The epitopes considered for analysis correspond to residues 18–26, 38–46, and 66–74 of Vpr. While the reference peptide of the epitope located at residues 18–26 (Table 18) of Vpr shows the estimate of half time of disassociation value of 1213.356, the variant amino acid at position 1–9 in the epitope predicted a lower value. The substitution of variant amino acids at residue position 2 of the epitope affected the half-time value considerably. Interestingly, substitution of R lowered the value to 0.233. Similarly, the substitution of F for L at position 9 of the epitope also lowered the value to 4.233. The analysis of the epitope corresponding to the residues 38–46 is shown in Table 19. The variant amino acids at residue 39 and 41 drastically lowered the value. The residue 46 showed contrasting values based on the nature of the variant amino acid present. The impact of polymorphisms on the epitope corresponding to the residues 66–74 is shown in Table 20. The results show that both the location and nature of the amino acid have an effect on the half-time disassociation of the molecule, which may lead to defective processing, presentation, and recognition of the epitope.

<p>Table 17</p>

The predicted HLA Class 1 CTL epitopes in HIV-1 Vpr

Location of the predicted epitope

Amino acid sequence

HLA allele

7 – 15

DQGPQREPY

B62

8 – 16

QGPQREPYN

Dd

11 – 19

QREPYNEWM

B_2705

14 – 22

PYNEWMLDL

A24, Kd

18 – 26

WMLDLLEDL

A_0201, A_0205, B_2705, B_3901, Db_revised, Kd

26 – 34

LKHEAVRHF

Cattle_A20

31 – 39

VRHFPRPWL

B_2705

34 – 42

FPRPWLHEL

B7, Cw_0401

38 – 46

WLHELGQQI

A_0201

39 – 47

LHELGQQIY

B_3801

49 – 57

TYGDTWEGV

Kd

60 – 68

IVRTLQQLL

B7

61 – 69

VRTLQQLLF

B_2702, B_2705

64 – 72

LQQLLFVHF

B62, B_2705, B_3902

65 – 73

QQLLFVHFR

A_3101, B_2705, Cattle_A20

66 – 74

QLLFVHFRI

A_0201

72 – 80

FRIGCQHSR

B_2705, Cattle_A20

79 – 87

SRIGIIRGR

B_2705, Cattle_A20

87 – 95

RRGRNGSGR

B_2705, Cattle_A20

 <p>Table 18</p>

Effect of variant amino acids on CTL epitope corresponding to residues 18–26 of Vpr

Amino Acid Sequence of Predicted Epitope

Scoreβ

Prototype sequence (start position 18)α

WMLDLLEDL

1,213.356

Natural variations observed at this epitope

GMLDLLEDL

263.773

RMLDLLEDL

263.773

WALDLLEDL

23.334

WILDLLEDL

231.004

WLLDLLEDL

1,680.031

WPLDLLEDL

10.967

WRLDLLEDL

0.233

WSLDLLEDL

10.967

WVLDLLEDL

147.003

WTLDLLEDL

23.334

WMIDLLEDL

327.934

WMMDLLEDL

1,213.356

WMVDLLEDL

327.934

WMLALLEDL

295.940

WMLELLEDL

1,213.356

WMLGLLEDL

295.940

WMLKLLEDL

295.940

WMLTLLEDL

295.940

WMLDLSEDL

527.546

WMLDLVEDL

1,213.356

WMLDLLDDL

1,213.356

WMLDLLGDL

321.911

WMLDLLKDL

2,476.237

WMLDLLQDL

2,476.237

WMLDLLRDL

495.247

WMLDLLEDF

4.233

WMLDLLEDI

592.569

α Accession No.: A1.TZ.01.A341_AY253314

β Estimate of Half Time of Disassociation of a Molecule Containing This Epitope

 <p>Table 19</p>

Effect of variant amino acids on CTL Epitope corresponding to residues 38–46 of Vpr

Amino Acid Sequence of Predicted Epitope

Scoreβ

Prototype sequence (start position 38)α

WLHELGQQI

196.763

Natural variations observed at this epitope

CLHELGQQI

42.774

FLHELGQQI

196.763

TLHELGQQI

42.774

YLHELGQQI

196.763

WFHELGQQI

0.137

WLIELGQQI

196.763

WLLELGQQI

728.022

WLMELGQQI

728.022

WLNELGQQI

196.763

WLQELGQQI

196.763

WLRELGQQI

14.954

WLTELGQQI

196.763

WLYELGQQI

629.64

WLHALGQQI

47.991

WLHDLGQQI

196.763

WLHGLGQQI

47.991

WLHHLGQQI

47.991

WLHNLGQQI

47.991

WLHQLGQQI

47.991

WLHRLGQQI

47.991

WLHSLGQQI

47.991

WLHWLGQQI

47.991

WLHECGQQI

196.763

WLHEFGQQI

747.698

WLHEIGQQI

196.763

WLHEMGQQI

196.763

WLHEVGQQI

196.763

WLHELGEQI

96.414

WLHELGHQI

196.763

WLHELGKQI

196.763

WLHELGLQI

196.763

WLHELGNQI

196.763

WLHELGRQI

39.353

WLHELGTQI

196.763

WLHELGVQI

196.763

WLHELGQFI

1082.194

WLHELGQHI

196.763

WLHELGQLI

196.763

WLHELGQWI

1082.194

WLHELGQYI

1082.194

WLHELGQQD

0.281

WLHELGQQV

1311.751

α Accession No.: A1.TZ.01.A341_AY253314

β Estimate of Half Time of Disassociation of a Molecule Containing This Epitope

 <p>Table 20</p>

Effect of variant amino acids on CTL Epitope corresponding to residues 66–74 of Vpr

Amino Acid Sequence of Predicted Epitope

Scoreβ

Prototype sequence (start position 66)α

QLLFVHFRI

223.888

Natural variations observed at this epitope

HLLFVHFRI

7.612

KLLFVHFRI

783.608

LLLFVHFRI

380.609

RLLFVHFRI

223.888

QFLFVHFRI

0.155

QILFVHFRI

30.785

QMLFVHFRI

161.697

QPLFVHFRI

1.461

QQLFVHFRI

22.700

QLIFVHFRI

60.510

QLMFVHFRI

223.888

QLPFVHFRI

60.510

QLRFVHFRI

4.599

QLLFVLFRI

514.942

QLLFVYFRI

335.832

QLLFVHLRI

38.601

QLLFVHYRI

38.601

QLLFVHSRI

38.601

QLLFVHFRF

1.599

QLLFVHFRH

1.599

QLLFVHFRL

458.437

QLLFVHFRM

106.613

QLLFVHFRN

1.599

QLLFVHFRS

1.599

QLLFVHFRT

159.920

QLLFVHFRV

1,492.586

α Accession No.: A1.TZ.01.A341_AY253314

β Estimate of Half Time of Disassociation of a Molecule Containing This Epitope

Discussion

Viral infections in individuals generally lead to a scenario where the virus is confronted by the host immune system involving both innate and adaptive immune responses. Regarding the latter, cellular and humoral immune responses have been shown to play a role in the control of infections of viruses including HIV-1 7071. It has been suggested that an understanding of the correlates of protective immunity is an important requirement for the development of vaccines against HIV-1. Several studies have been published on this subject 717273. These studies point out a role for CD8+ and CD4+ T cell responses and neutralizing antibodies in the control of HIV-1 replication. For example, it has been reported that CD8+ cells control HIV-1 in the acutely infected individuals 456. The relevance of CD8+ T cells for the control of virus infection was also shown in the case of SIV infected rhesus macaques 7475. Recently, the published data on CD8+ T cells in acute and chronic HIV-1 infection revealed that CTL epitopes are present in all of the proteins encoded by HIV-1. Virus replication, however, is not completely contained due to the emergence of CTL escape variant viruses. Based on this, it is suggested that vaccine efforts to control HIV-1 should take into account the high genetic variability noted among HIV-1.

The continued emergence of genetic variants is a characteristic feature of RNA viruses. RNA dependent RNA polymerase and reverse transcriptase are error-prone enzymes and have been implicated as a cause for the generation of variants 7677. The mutational changes in the protease and reverse transcriptase, depending on their location, may impact on their binding inhibitors targeting these enzymes. The viruses containing alterations may then be able to evade the inhibitory activities of the agents and are designated as drug-resistant variants. Similarly, the mutations in Env, Tat, and possibly other proteins can also evade the neutralizing antibody, CTL and T-helper cell responses 1271. The emergence of escape variants eventually repopulates the body in the face of immune responses against the virus. It has been suggested that immune escape may be a key step in the evolution of HIV-1 30787980.

In an effort to understand the overall polymorphisms in a HIV-1 gene product, we undertook a comprehensive analysis of the predicted amino acid sequences of Vpr from diverse HIV-1 subtypes. Considering the genetic variation noted in diverse HIV-1 39, our hypothesis is that the differences in Vpr and other viral proteins may enable the viruses to escape the host immunological pressures. To address this issue, we have initially compiled the polymorphisms in Vpr at the level of individual amino acid. Vpr contains only 96 amino acids. Hence, the small size of the protein is an advantage for a comprehensive analysis. For this purpose, we have turned to the Vpr sequences which are available in the HIV database and also sequences from specific groups such as HIV-1 positive long-term non-progressors. A total of 976 predicted Vpr amino acid sequences were used for our studies. The analysis revealed several characteristic features with respect to the individual amino acids in the Vpr. Of the 96 amino acids, all the amino acids except the initiator methionine have the propensity to change. This indicates that Vpr molecule is highly flexible in nature. The frequency of the variant amino acids, calculated for subtype B Vpr at the level of individual residue, revealed that substitution is very low for most of the residues. This suggests that many of the substitutions in Vpr may compromise the function and possibly the fitness of the virus. Interestingly, there are several amino acids that can accommodate ten or more alterations. We designate such amino acids as hot spots in Vpr which include residues 15, 16, 28, 36, 37, 48, 55, 58, 77, 84, 86 and 89. The underlying basis for the extensive genetic changes in specific regions of Vpr is not clear. It is likely that the error-prone reverse transcriptase, the secondary structure of RNA and other factors, either alone and/or in combination may play a role in the generation of genetic variants. In this regard, Yusim et al. 28 have noted that Integrase (IN) exhibits the least variability and Vpu exhibits the highest variability. Boutwell and Essex 27 also showed that the proportion of polymorphic amino acids ranged from a low of 55% (RT, IN) to a high of 94% (Vpu). In our analysis, Vpr variability is high which may likely be due to the inclusion of diverse isolates including the HIV-1 progenitor virus SIVcpz.

Vpr is known as a highly immunogenic protein. The presence of CTL epitopes verified through experimental approaches has been reported by several groups 12. These include the region encompassing residues 9–70 of Vpr. Of the 96 residues, 62 (65%) have been shown to be associated with experimentally defined CTL epitopes. The data presented in Table 16 show that there are polymorphisms with respect to the experimentally verified CTL epitopes. The presence of variant amino acids at distinct locations within the epitope is likely to impact the CTL epitope. Further, we have also evaluated the effect of Vpr polymorphisms on CTL epitopes using the bioinformatics approach by calculating the estimate of half time of disassociation of the molecule containing the epitope. Such an analysis predicted several CTL epitopes all over Vpr including the C-terminus with respect to specific HLA class 1 molecules. The detailed analysis was carried out for different HLA alleles (HLA-A2, Cw-4, HLA-B7 and HLA-B2705) involving a total of 12 epitopes. The polymorphisms have also been analyzed for three predicted epitopes corresponding to residues 18–26, 38–46, and 66–74. The substitution of the variant amino acids for the residues comprising the epitope resulted in a drastic reduction in the value corresponding to the half time of the disassociation of the molecule containing the epitope. It should, however be noted that additional in vitro binding studies are necessary to confirm the predicted values.

Based on the data presented here, the amino acid polymorphisms noted in Vpr have the potential to contribute to the escape of the virus along with the epitopes present in other HIV-1 proteins 30. It is also likely that the information regarding the polymorphisms at the CTL epitope will provide an opportunity to create an epitope-based vaccine that will exert control over viral isolates from different parts of the world. It is important to mention that the extensive HLA-associated amino acid polymorphisms noted here may also impact on the structure/function of Vpr and fitness of the virus 108182838485. The biological sources used for generating the sequence information of vpr include tissues from infected individuals, plasma viral RNA, and cloned viral DNA. For this reason, the Vpr sequences considered here for the analysis may be derived from both infectious and non-infectious viral genomes. Hence, there is a possibility that the amino acid polymorphisms noted here may or may not have a chance to be acted upon by CTL and T-helper cell pressures. It is known that amino acids in the proximal region of the epitope can also influence their immunogenic potential. The amino acid polymorphisms noted in the putative CTL epitopes can have an effect at a single and/or multiple levels in the generation of immune response: i) The mutations may eliminate the binding of the peptide to the appropriate HLA molecule, which will be presented on the cell surface. ii) Mutations may also disrupt the interaction with the T-cell receptors. iii) Mutations may disrupt the intracellular processing of the peptides. This results in the escape of the cells expressing the viral proteins from the surveillance of CD8+ T cells. The variant amino acids present in the proximal or far away from the epitope could influence through interference with the processing of the peptide from the protein. With regard to the latter, the variant amino acids may be either independent or compensatory in relation to changes in specific residues of Vpr. In addition, variant amino acids, which are part of overlapping epitopes presented by different HLA molecule, can also exert an influence on the epitope 30.

HIV variability is an important factor that should be taken into account in the efforts directed towards the development of vaccines against HIV-1. In order for the vaccines to be effective against diverse HIV-1, strategies that are being considered include consensus sequence approaches and polyvalent vaccines in the form of a mixture of genes/proteins from different subtypes of HIV-1. Despite the extensive variability reported for HIV-1, the nature and extent of variation has not been systematically investigated. Such an analysis is difficult to carry out for HIV-1 Gag, Pol or Env protein due to its size. It is for this reason that we have selected Vpr, a small protein. The results presented for Vpr here are interesting and novel as they describe genetic variation involving global HIV-1. Surprisingly, the frequency of the variant amino acids for most of the residues is low. This suggests that majority of the residues cluster around a sequence shared by HIV-1 isolates of different subtypes. It is likely that the influence of the residues on the fitness of the virus counters the variability, thus limiting the genetic variation. The information on Vpr polymorphisms will be of value for the development of vaccines based on the auxiliary genes of HIV-1.

Authors' contributions

AS, VA, AK, AB, VS, RC and AC participated in the analysis of the predicted amino acid sequences of Vpr. SM, DD and BS provided information regarding the structure-function of Vpr. NM and RM contributed to the analysis of polymorphisms in Vpr from the structural angle. AS, VA, SM, VS, AC, and RC were involved in the preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported in part by grant R56-AI50463 from NIAID, National Institute of Health to VA.

 <p>NK cell function in HIV-1 infection</p> Alter G Altfeld M Curr Mol Med 2006 6 621 629 10.2174/156652406778195035 17022732 <p>The role of CD8+ T-cell response in HIV infection</p> Benito JM Lopez M Soriano V AIDS Rev 2004 6 79 88 15332430 <p>T cell immunity to HIV: defining parameters of protection</p> Maecker HT Maino VC Curr HIV Res 2003 1 249 259 10.2174/1570162033485294 15043207 <p>Virus escape from CTL recognition</p> Koup RA J Exp Med 1994 180 779 782 2191640 7520471 10.1084/jem.180.3.779 <p>Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA</p> Ogg GS Jin X Bonhoeffer S Dunbar PR Nowak MA Monard S Segal JP Cao Y Rowland-Jones SL Cerundolo V Science 1998 279 2103 2106 10.1126/science.279.5359.2103 9516110 <p>Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection</p> Borrow P Lewicki H Hahn BH Shaw GM Oldstone MB J Virol 1994 68 6103 6110 237022 8057491 <p>Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial</p> Matano T Kobayashi M Igarashi H Takeda A Nakamura H Kano M Sugimoto C Mori K Iida A Hirata T J Exp Med 2004 199 1709 1718 2212812 15210746 10.1084/jem.20040432 <p>Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection</p> O'Connor D Friedrich T Hughes A Allen TM Watkins D Immunol Rev 2001 183 115 126 10.1034/j.1600-065x.2001.1830110.x 11782252 <p>Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia</p> Allen TM O'Connor DH Jing P Dzuris JL Mothe BR Vogel TU Dunphy E Liebl ME Emerson C Wilson N Nature 2000 407 386 390 10.1038/35036559 11014195 <p>HIV and SIV CTL escape: implications for vaccine design</p> Goulder PJ Watkins DI Nat Rev Immunol 2004 4 630 640 10.1038/nri1417 15286729 <p>Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants</p> Fischer W Perkins S Theiler J Bhattacharya T Yusim K Funkhouser R Kuiken C Haynes B Letvin NL Walker BD Nat Med 2007 13 100 106 10.1038/nm1461 17187074 Korber BTM Brander C Hayens BF Koup R Moore JP Walker BD Watkins DI HIV Molecular Immunology Los Alamos National Laboratory, Los Alamos, NM 2007 <p>HIV-1 replication</p> Freed EO Somat Cell Mol Genet 2001 26 13 33 10.1023/A:1021070512287 12465460 <p>HIVs and their replication</p> Freed EO Martin MA "Fields' Virology" Lippincott Williams & Wilkins, Philadelphia Knipe DM, Howley PM 2001 1971 2041 <p>Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein</p> Sheehy AM Gaddis NC Choi JD Malim MH Nature 2002 418 646 650 10.1038/nature00939 12167863 <p>The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA</p> Zhang H Yang B Pomerantz RJ Zhang C Arunachalam SC Gao L Nature 2003 424 94 98 1350966 12808465 10.1038/nature01707 <p>HIV-1 Vpr: genetic diversity and functional features from the perspective of structure</p> Tungaturthi PK Sawaya BE Ayyavoo V Murali R Srinivasan A DNA Cell Biol 2004 23 207 222 10.1089/104454904773819798 15142378 <p>Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production</p> Varthakavi V Smith RM Bour SP Strebel K Spearman P Proc Natl Acad Sci USA 2003 100 15154 15159 299932 14657387 10.1073/pnas.2433165100 <p>Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4</p> Willey RL Maldarelli F Martin MA Strebel K J Virol 1992 66 7193 7200 240416 1433512 <p>Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors</p> James CO Huang MB Khan M Garcia-Barrio M Powell MD Bond VC J Virol 2004 78 3099 3109 353732 14990729 10.1128/JVI.78.6.3099-3109.2004 <p>Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein</p> Arold ST Baur AS Trends Biochem Sci 2001 26 356 363 10.1016/S0968-0004(01)01846-1 11406408 <p>HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell</p> Geleziunas R Xu W Takeda K Ichijo H Greene WC Nature 2001 410 834 838 10.1038/35071111 11298454 <p>HIV-1 Nef protein-induced apoptotic cytolysis of a broad spectrum of uninfected human blood cells independently of CD95(Fas)</p> Okada H Takei R Tashiro M FEBS Lett 1997 414 603 606 10.1016/S0014-5793(97)01080-6 9323045 <p>Biology of the HIV Nef protein</p> Das SR Jameel S Indian J Med Res 2005 121 315 332 15817946 <p>Pathogenesis and medical aspects of HIV-1 infection</p> Cohen OJ Fauci AS "Fields' Virology" Lippincott Williams & Wilkins, Philadelphia 2001 2043 2094 <p>"HIV and the Pathogenesis of AIDS"</p> Levy JA ASM Press, Washington, DC 1998 <p>Identification of HLA class I-associated amino acid polymorphisms in the HIV-1C proteome</p> Boutwell CL Essex M AIDS Res Hum Retroviruses 2007 23 165 174 10.1089/aid.2006.0131 17263647 <p>Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation</p> Yusim K Kesmir C Gaschen B Addo MM Altfeld M Brunak S Chigaev A Detours V Korber BT J Virol 2002 76 8757 8768 136996 12163596 10.1128/JVI.76.17.8757-8768.2002 <p>Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes</p> Rousseau CM Birditt BA McKay AR Stoddard JN Lee TC McLaughlin S Moore SW Shindo N Learn GH Korber BT J Virol Methods 2006 136 118 125 10.1016/j.jviromet.2006.04.009 16701907 <p>HLA Class-I Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load</p> Rousseau CM Daniels MG Carlson JM Kadie C Crawford H Prendergast A Matthews P Payne R Rolland M Raugi DN J Virol 2008 82 6434 46 18434400 10.1128/JVI.02455-07 <p>Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells?</p> Azad AA Biochem Biophys Res Commun 2000 267 677 685 10.1006/bbrc.1999.1708 10673351 <p>HIV-1, Vpr and the cell cycle</p> Emerman M Curr Biol 1996 6 1096 1103 10.1016/S0960-9822(02)00676-0 8805364 <p>Viral protein R of HIV-1</p> Bukrinsky M Adzhubei A Rev Med Virol 1999 9 39 49 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3 10371671 <p>HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology</p> Emerman M Malim MH Science 1998 280 1880 1884 10.1126/science.280.5371.1880 9632380 <p>Near full-length genome characterization of three additional HIV type 1 CRF13_cpx strains from Cameroon</p> Luk KC Holzmayer V Yamaguchi J Swanson P Brennan CA Ngansop C Mbanya D Gayum H Djuidje MN Ndembi N AIDS Res Hum Retroviruses 2007 23 297 302 10.1089/aid.2006.0177 17331036 <p>Genomic analysis of HIV type 1 strains derived from a mother and child pair of long-term nonprogressors</p> Reinis M Weiser B Kuiken C Dong T Lang D Nachman S Zhang Y Rowland-Jones S Burger H AIDS Res Hum Retroviruses 2007 23 309 315 10.1089/aid.2006.0180 17331038 <p>Molecular characterization of the HIV type 1 subtype C accessory genes vif, vpr, and vpu</p> Bell CM Connell BJ Capovilla A Venter WD Stevens WS Papathanasopoulos MA AIDS Res Hum Retroviruses 2007 23 322 330 10.1089/aid.2006.0181 17331040 <p>Molecular Characterization of the HIV Type 1 vpr Gene in Infected Chinese Former Blood/Plasma Donors at Different Stages of Diseases</p> Shen C Gupta P Wu H Chen X Huang X Zhou Y Chen Y AIDS Res Hum Retroviruses 2008 24 661 666 10.1089/aid.2007.0270 18366311 <p>Consistent risk group-associated differences in human immunodeficiency virus type 1 vpr, vpu and V3 sequences despite independent evolution</p> Kuiken CL Cornelissen MT Zorgdrager F Hartman S Gibbs AJ Goudsmit J J Gen Virol 1996 77 Pt 4 783 792 10.1099/0022-1317-77-4-783 8627267 <p>NMR structure of the HIV-1 regulatory protein VPR</p> Morellet N Bouaziz S Petitjean P Roques BP J Mol Biol 2003 327 215 227 10.1016/S0022-2836(03)00060-3 12614620 <p>Evidence for a cytopathogenicity determinant in HIV-1 Vpr</p> Somasundaran M Sharkey M Brichacek B Luzuriaga K Emerman M Sullivan JL Stevenson M Proc Natl Acad Sci USA 2002 99 9503 9508 123170 12093916 10.1073/pnas.142313699 <p>Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo</p> Votteler J Studtrucker N Sorgel S Munch J Rucker E Kirchhoff F Schick B Henklein P Fossen T Bruns K J Virol 2007 81 9572 9576 1951402 17553868 10.1128/JVI.02803-06 <p>Nuclear localization of Vpr is crucial for the efficient replication of HIV-1 in primary CD4+ T cells</p> Iijima S Nitahara-Kasahara Y Kimata K Zhong Zhuang W Kamata M Isogai M Miwa M Tsunetsugu-Yokota Y Aida Y Virology 2004 327 249 261 10.1016/j.virol.2004.06.024 15351213 <p>Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr</p> Di Marzio P Choe S Ebright M Knoblauch R Landau NR J Virol 1995 69 7909 7916 189735 7494303 <p>Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation</p> Mahalingam S Khan SA Jabbar MA Monken CE Collman RG Srinivasan A Virology 1995 207 297 302 10.1006/viro.1995.1081 7871742 <p>Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation</p> Mahalingam S Khan SA Murali R Jabbar MA Monken CE Collman RG Srinivasan A Proc Natl Acad Sci USA 1995 92 3794 3798 42048 7731985 10.1073/pnas.92.9.3794 <p>Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis</p> Paxton W Connor RI Landau NR J Virol 1993 67 7229 7237 238185 8230445 <p>The first HxRxG motif in simian immunodeficiency virus mac239 Vpr is crucial for G(2)/M cell cycle arrest</p> Mueller SM Lang SM J Virol 2002 76 11704 11709 136740 12388729 10.1128/JVI.76.22.11704-11709.2002 <p>Functional conservation of HIV-1 Vpr and variability in a mother-child pair of long-term non-progressors</p> Zhao Y Chen M Wang B Yang J Elder RT Song XQ Yu M Saksena NK Virus Res 2002 89 103 121 10.1016/S0168-1702(02)00127-2 12367754 <p>Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication</p> Thotala D Schafer EA Tungaturthi PK Majumder B Janket ML Wagner M Srinivasan A Watkins S Ayyavoo V Virology 2004 328 89 100 10.1016/j.virol.2004.07.013 15380361 <p>Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages</p> Jacquot G Le Rouzic E David A Mazzolini J Bouchet J Bouaziz S Niedergang F Pancino G Benichou S Retrovirology 2007 4 84 2211753 18039376 10.1186/1742-4690-4-84 <p>Human immunodeficiency virus type 1 vpr protein transactivation function: mechanism and identification of domains involved</p> Forget J Yao XJ Mercier J Cohen EA J Mol Biol 1998 284 915 923 10.1006/jmbi.1998.2206 9837715 <p>Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation</p> Yao XJ Subbramanian RA Rougeau N Boisvert F Bergeron D Cohen EA J Virol 1995 69 7032 7044 189623 7474123 <p>Mutational analysis of Vpr-induced G2 arrest, nuclear localization, and cell death in fission yeast</p> Chen M Elder RT Yu M O'Gorman MG Selig L Benarous R Yamamoto A Zhao Y J Virol 1999 73 3236 3245 104087 10074177 <p>HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection</p> Vodicka MA Koepp DM Silver PA Emerman M Genes Dev 1998 12 175 185 316441 9436978 10.1101/gad.12.2.175 <p>Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr</p> Singh SP Tomkowicz B Lai D Cartas M Mahalingam S Kalyanaraman VS Murali R Srinivasan A J Virol 2000 74 10650 10657 110939 11044109 10.1128/JVI.74.22.10650-10657.2000 <p>Two putative alpha-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms</p> Kamata M Aida Y J Virol 2000 74 7179 7186 112238 10888660 10.1128/JVI.74.15.7179-7186.2000 <p>Vpr cytopathicity independent of G2/M cell cycle arrest in human immunodeficiency virus type 1-infected CD4+ T cells</p> Bolton DL Lenardo MJ J Virol 2007 81 8878 8890 1951439 17553871 10.1128/JVI.00122-07 <p>Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages</p> Sherman MP de Noronha CM Eckstein LA Hataye J Mundt P Williams SA Neidleman JA Goldsmith MA Greene WC J Virol 2003 77 7582 7589 164827 12805458 10.1128/JVI.77.13.7582-7589.2003 <p>Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr</p> Mahalingam S Ayyavoo V Patel M Kieber-Emmons T Weiner DB J Virol 1997 71 6339 6347 191907 9261351 <p>DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest</p> Tan L Ehrlich E Yu XF J Virol 2007 81 10822 10830 2045451 17626091 10.1128/JVI.01380-07 <p>Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle</p> Hrecka K Gierszewska M Srivastava S Kozaczkiewicz L Swanson SK Florens L Washburn MP Skowronski J Proc Natl Acad Sci USA 2007 104 11778 11783 1906728 17609381 10.1073/pnas.0702102104 <p>Transcription factor TFIIH components enhance the GR coactivator activity but not the cell cycle-arresting activity of the human immunodeficiency virus type-1 protein Vpr</p> Kino T Tsukamoto M Chrousos G Biochem Biophys Res Commun 2002 298 17 23 10.1016/S0006-291X(02)02442-7 12379213 <p>Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest</p> Sherman MP de Noronha CM Pearce D Greene WC J Virol 2000 74 8159 8165 112350 10933727 10.1128/JVI.74.17.8159-8165.2000 <p>A novel inducible expression system to study transdominant mutants of HIV-1 Vpr</p> Zhou Y Ratner L Virology 2001 287 133 142 10.1006/viro.2001.1031 11504548 <p>Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction</p> Kitayama H Miura Y Ando Y Hoshino S Ishizaka Y Koyanagi Y J Virol 2008 82 2528 2542 2258941 18094160 10.1128/JVI.02094-07 <p>Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest</p> Zhou Y Lu Y Ratner L Virology 1998 242 414 424 10.1006/viro.1998.9028 9514978 <p>Phosphorylation of Vpr regulates HIV type 1 nuclear import and macrophage infection</p> Agostini I Popov S Hao T Li JH Dubrovsky L Chaika O Chaika N Lewis R Bukrinsky M AIDS Res Hum Retroviruses 2002 18 283 288 10.1089/088922202753472856 11860675 <p>Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys</p> Barouch DH Kunstman J Glowczwskie J Kunstman KJ Egan MA Peyerl FW Santra S Kuroda MJ Schmitz JE Beaudry K J Virol 2003 77 7367 7375 164797 12805435 10.1128/JVI.77.13.7367-7375.2003 <p>Immunological and pharmacological approaches to the control of retroviral infections</p> Emini EA Fan HY "Retroviruses" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York Coffin JM, Hughes SH, Varmus HE 1997 637 706 <p>Antibody-based HIV-1 vaccines: recent developments and future directions</p> Montefiori D Sattentau Q Flores J Esparza J Mascola J PLoS Med 2007 4 e348 2100141 18052607 10.1371/journal.pmed.0040348 <p>Hitting HIV where it hurts: an alternative approach to HIV vaccine design</p> Altfeld M Allen TM Trends Immunol 2006 27 504 510 10.1016/j.it.2006.09.007 16997629 <p>HIV vaccine design and the neutralizing antibody problem</p> Burton DR Desrosiers RC Doms RW Koff WC Kwong PD Moore JP Nabel GJ Sodroski J Wilson IA Wyatt RT Nat Immunol 2004 5 233 236 10.1038/ni0304-233 14985706 <p>Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques</p> Jin X Bauer DE Tuttleton SE Lewin S Gettie A Blanchard J Irwin CE Safrit JT Mittler J Weinberger L J Exp Med 1999 189 991 998 2193038 10075982 10.1084/jem.189.6.991 <p>Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes</p> Schmitz JE Kuroda MJ Santra S Sasseville VG Simon MA Lifton MA Racz P Tenner-Racz K Dalesandro M Scallon BJ Science 1999 283 857 860 10.1126/science.283.5403.857 9933172 <p>HIV-1 sequence variation: drift, shift, and attenuation</p> Malim MH Emerman M Cell 2001 104 469 472 10.1016/S0092-8674(01)00234-3 11239404 <p>Selection forces and constraints on retroviral sequence variation</p> Overbaugh J Bangham CR Science 2001 292 1106 1109 10.1126/science.1059128 11352065 <p>Founder effects in the assessment of HIV polymorphisms and HLA allele associations</p> Bhattacharya T Daniels M Heckerman D Foley B Frahm N Kadie C Carlson J Yusim K McMahon B Gaschen B Science 2007 315 1583 1586 10.1126/science.1131528 17363674 <p>AIDS vaccines: on the trail of two trials</p> Moore JP Nature 2002 415 365 366 10.1038/415365a 11807523 <p>Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1</p> Brumme ZL Brumme CJ Heckerman D Korber BT Daniels M Carlson J Kadie C Bhattacharya T Chui C Szinger J PLoS Pathog 2007 3 e94 1904471 17616974 10.1371/journal.ppat.0030094 <p>Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection</p> Crawford H Prado JG Leslie A Hue S Honeyborne I Reddy S Stok van der M Mncube Z Brander C Rousseau C J Virol 2007 81 8346 8351 1951305 17507468 10.1128/JVI.00465-07 <p>Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes</p> Yang OO Sarkis PT Ali A Harlow JD Brander C Kalams SA Walker BD J Exp Med 2003 197 1365 1375 2193781 12743169 10.1084/jem.20022138 <p>Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope</p> Peyerl FW Bazick HS Newberg MH Barouch DH Sodroski J Letvin NL J Virol 2004 78 13901 13910 533946 15564498 10.1128/JVI.78.24.13901-13910.2004 <p>Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA</p> Leslie A Kavanagh D Honeyborne I Pfafferott K Edwards C Pillay T Hilton L Thobakgale C Ramduth D Draenert R J Exp Med 2005 201 891 902 2213090 15781581 10.1084/jem.20041455 <p>Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response</p> Friedrich TC Frye CA Yant LJ O'Connor DH Kriewaldt NA Benson M Vojnov L Dodds EJ Cullen C Rudersdorf R J Virol 2004 78 2581 2585 369222 14963161 10.1128/JVI.78.5.2581-2585.2004 <p>The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design</p> Altfeld M Allen TM Kalife ET Frahm N Addo MM Mothe BR Rathod A Reyor LL Harlow J Yu XG J Virol 2005 79 5000 5005 1069570 15795285 10.1128/JVI.79.8.5000-5005.2005 <p>CD8+ T-cell responses to different HIV proteins have discordant associations with viral load</p> Kiepiela P Ngumbela K Thobakgale C Ramduth D Honeyborne I Moodley E Reddy S de Pierres C Mncube Z Mkhwanazi N Nat Med 2007 13 46 53 10.1038/nm1520 17173051 <p>Vpr is preferentially targeted by CTL during HIV-1 infection</p> Altfeld M Addo MM Eldridge RL Yu XG Thomas S Khatri A Strick D Phillips MN Cohen GB Islam SA J Immunol 2001 167 2743 2752 11509618 <p>Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection</p> Addo MM Yu XG Rosenberg ES Walker BD Altfeld M DNA Cell Biol 2002 21 671 678 10.1089/104454902760330219 12396610 <p>Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load</p> Addo MM Yu XG Rathod A Cohen D Eldridge RL Strick D Johnston MN Corcoran C Wurcel AG Fitzpatrick CA J Virol 2003 77 2081 2092 140965 12525643 10.1128/JVI.77.3.2081-2092.2003 <p>Identification of HIV-1 specific T lymphocyte responses in highly exposed persistently seronegative Chinese</p> Liu HW Hong KX Ma J Yuan L Liu S Chen JP Zhang YZ Ruan YH Xu JQ Shao YM Chin Med J (Engl) 2006 119 1616 1621 17042974 <p>Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection</p> Cao J McNevin J Holte S Fink L Corey L McElrath MJ J Virol 2003 77 6867 6878 156203 12768006 10.1128/JVI.77.12.6867-6878.2003 <p>Immunodominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics</p> Lichterfeld M Yu XG Le Gall S Altfeld M Trends Immunol 2005 26 166 171 10.1016/j.it.2005.01.003 15745859 <p>Identification of HIV-derived HLA class I restricted CTL epitope: Insights into TCR repertoire, CTL escape and viral fitness</p> Frahm N Linde C Brander C "HIV Molecular Immunology 2006" Los Alamos National Laboratory, Theoritical Biology and Biophysics, Los Alamos, New Mexico 2007 3 <p>HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response</p> Feeney ME Tang Y Pfafferott K Roosevelt KA Draenert R Trocha A Yu XG Verrill C Allen T Moore C J Immunol 2005 174 7524 7530 15944251 <p>Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C</p> Novitsky V Cao H Rybak N Gilbert P McLane MF Gaolekwe S Peter T Thior I Ndung'u T Marlink R J Virol 2002 76 10155 10168 136554 12239290 10.1128/JVI.76.20.10155-10168.2002 <p>Extensive HLA class I allele promiscuity among viral CTL epitopes</p> Frahm N Yusim K Suscovich TJ Adams S Sidney J Hraber P Hewitt HS Linde CH Kavanagh DG Woodberry T Eur J Immunol 2007 37 2419 2433 10.1002/eji.200737365 17705138 <p>Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif</p> Altfeld MA Livingston B Reshamwala N Nguyen PT Addo MM Shea A Newman M Fikes J Sidney J Wentworth P J Virol 2001 75 1301 1311 114036 11152503 10.1128/JVI.75.3.1301-1311.2001 <p>Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes</p> Corbet S Nielsen HV Vinner L Lauemoller S Therrien D Tang S Kronborg G Mathiesen L Chaplin P Brunak S J Gen Virol 2003 84 2409 2421 10.1099/vir.0.19152-0 12917462 <p>Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection</p> Yu XG Addo MM Rosenberg ES Rodriguez WR Lee PK Fitzpatrick CA Johnston MN Strick D Goulder PJ Walker BD Altfeld M J Virol 2002 76 8690 8701 136975 12163589 10.1128/JVI.76.17.8690-8701.2002 <p>Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes</p> Bernardin F Kong D Peddada L Baxter-Lowe LA Delwart E J Virol 2005 79 11523 11528 1193571 16103205 10.1128/JVI.79.17.11523-11528.2005 <p>Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA</p> Kiepiela P Leslie AJ Honeyborne I Ramduth D Thobakgale C Chetty S Rathnavalu P Moore C Pfafferott KJ Hilton L Nature 2004 432 769 775 10.1038/nature03113 15592417 <p>De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection</p> Allen TM Yu XG Kalife ET Reyor LL Lichterfeld M John M Cheng M Allgaier RL Mui S Frahm N J Virol 2005 79 12952 12960 1235830 16188997 10.1128/JVI.79.20.12952-12960.2005 <p>Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120</p> Liu F Bergami PL Duval M Kuhrt D Posner M Cavacini L AIDS Res Hum Retroviruses 2003 19 597 607 10.1089/088922203322230969 12908937 <p>Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity</p> Propato A Schiaffella E Vicenzi E Francavilla V Baloni L Paroli M Finocchi L Tanigaki N Ghezzi S Ferrara R Hum Immunol 2001 62 561 576 10.1016/S0198-8859(01)00245-2 11390031 <p>Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays</p> Goulder PJ Addo MM Altfeld MA Rosenberg ES Tang Y Govender U Mngqundaniso N Annamalai K Vogel TU Hammond M J Virol 2001 75 1339 1347 114040 11152507 10.1128/JVI.75.3.1339-1347.2001